1) [18F]-FDG uptake dose–response correlates with radiation pneumonitis in lung cancer patients. Matthew R. McCurdy, Richard Castillo, Josue Martinez, Mohammad Najeeb Al Hallack, Jessica Lichter, Nicolas Zouain, Thomas Guerrero. Radiotherapy & Oncology. 2012; 104(1):52-57.

2)  Adjuvant Radiotherapy in Non-small Cell Lung Cancer with Pathological Stage I: Definitive Results of a Phase III Randomized Trial. Trodella, L, Garnone, P, Valente, S, et al. Radiotherapy and Oncology. 2002;62: 11-19.

3) Automated volumetric modulated Arc therapy treatment planning for stage III lung cancer: how does it compare with intensity-modulated radio therapy? Quan EM. Chang JY. Liao Z. Xia T. Yuan Z. Liu H. Li X. Wages CA. Mohan R. Zhang X.
International Journal of Radiation Oncology, Biology, Physics. 2012; 84(1):e69-76.

4) Brachial plexopathy in apical non-small cell lung cancer treated with definitive radiation: dosimetric analysis and clinical implications. Eblan MJ, Corradetti MN, Lukens JN, Xanthopoulos E, Mitra N, Christodouleas JP, Grover S, Fernandes AT, Langer CJ, Evans TL, Stevenson J, Rengan R, Apisarnthanarax S. International Journal of Radiation Oncology Biology Physics. 2013; 85(1):175-81.

5) Central-Airway Necrosis after Stereotactic Body-Radiation Therapy. Michael N. Corradetti, Andrew R. Haas, Ramesh Rengan. New England Journal of Medicine. 2012; 366:2327-2329.

6) Dose Escalation, Not “New Biology,” Can Account for the Efficacy of Stereotactic Body Radiation Therapy With
Non-Small Cell Lung Cancer. J. Martin Brown, David J. Brenner, David J. Carlson, PhD. International Journal of Radiation Oncology Biology Physics. 2013; 85(5): 1159-1160.

7) Dose-Escalation Study of Thoracic Radiotherapy in Combination With Pemetrexed Plus Cisplatin Followed by  Pemetrexed Consolidation Therapy in Japanese Patients With Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. Niho, S, Kubota, K, Nihei, K, et al. Clinical Lung Cancer. 2012; In Press Online May 24.

8) Limited field irradiation in early stage (TI_zN0) non-small cell lung cancer.  B.J. Slotman, I.E. Antonisse, K.H. Njo. Radiotherapy and Oncology. 1996; 41 :41-44.

9) Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience. Jiang ZQ, Yang K, Komaki R, Wei X, Tucker SL, Zhuang Y, Martel MK, Vedam S, Balter P, Zhu G, Gomez D, Lu C, Mohan R, Cox JD, Liao Z. International Journal of Radiation Oncology Biology Physics. 2012;83(1):332-9.

10) Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, Choucair A, Fox S, Suh JH, Roberge D, Kavadi V, Bentzen SM, Mehta MP, Watkins-Bruner D; for the Radiation Therapy Oncology Group (RTOG). International Journal of Radiation Oncology  Biology Physics. 2013; 84(3): S1-S2.

11) Natural history of stage I non-small cell lung cancer: implications for early detection. Raz DJ. Zell JA. Ou SH. Gandara DR. Anton-Culver H. Jablons DM. Chest. 2007; 132(1):193-9.

12) Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.  N C Choi, J E Herndon 2nd, J Rosenman, R W Carey, C T Chung, S Bernard, L Leone, S Seagren, and M Green. Journal of Clinical Oncology.1998; 16(11):3528-36.

13) Pleural Intensity-Modulated Radiotherapy for Malignant Pleural Mesothelioma. Kenneth E. Rosenzweig, Marjorie G. Zauderer, Benjamin Laser, Lee M. Krug, Ellen Yorke, Camelia S. Sima, Andreas Rimner, Raja Flores, Valerie Rusch. International Journal of Radiation Oncology Biology Physics. 2012; 83(4):1278e1283.

14) Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. The Lancet. 1998; 352(9124):257-263.

15) Postoperative radiotherapy in radically resected non-small cell lung cancer. Mayer R, Smolle-Juettner FM, Szolar D, Stuecklschweiger GF, Quehenberger F, Friehs G, Hackl A. Chest. 1997;112(4):954-9.

16) Predicting the need for palliative thoracic radiation after first-line chemotherapy for advanced nonsmall cell lung carcinoma.Daniel S. Higginson, Ronald C. Chen, David E. Morris, Jan Halle, Julian G. Rosenman, Mark A. Socinski and Lawrence B. Marks. Cancer. 2012; 118(10): 2744–2751.

17) Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Palma DA, Senan S, Tsujino K, Barriger RB, Rengan R, Moreno M, Bradley JD, Kim TH, Ramella S, Marks LB, De Petris L, Stitt L, Rodrigues G. International Journal of Radiation Oncology Biology Physics. 2013;85(2):444-50.

18) Predicting Symptomatic Radiation Pneumonitis After Concurrent Chemoradiation Therapy for Non-small Cell Lung Cancer: Results of an International Individual Patient Data Meta-analysis. D.A. Palma, S. Senan, K. Tsujino, R.B. Barriger, R. Rengan, M. Moreno, J.D. Bradley, T. Hyun Kim, L.B. Marks, G. Rodrigues. International Journal of Radiation Oncology Biology Physics. 2012; 84(3):S549.

19) Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer. Ben Slotman, M.D., Ph.D., Corinne Faivre-Finn, M.D., Ph.D., Gijs Kramer, M.D., Elaine Rankin, M.D., Michael Snee, D.M., Matthew Hatton, F.R.C.R., Pieter Postmus, M.D., Ph.D., Laurence Collette, Ph.D., Elena Musat, M.D., and Suresh Senan, Ph.D., F.R.C.R. for the EORTC Radiation Oncology Group and Lung Cancer Group. New England Journal of Medicine. 2007; 357:664-672.

20) Pulmonary atelectasis after stereotactic ablative radiotherapy for a central lung tumor. Senthi S. Ullmann EF. Senan S.. Journal of Thoracic Oncology. 2013; 8(11):e94-5.

21) Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. The National Lung Screening Trail  Research Team. New England Journal of Medicine 2011; 365: 395-409.

22) Role of Radiation Therapy in the Combined Modality Treatment of Patients with Extensive Disease Small-Cell Lung Cancer:  A Randomized Study. Jeremic, B, Shibamoto, Y, Nikolic, N, et al. Journal of Clinical Oncology. 1999;  17(7): 2092-2099.

23) Stage III vs. Stage IV Lung Cancer: “Crossing a Great Divide”. Marks, LB, Saynak, M, Christodouleas, JP. Lung Cancer. 2010; 67(1):1-3.

24) Stereotactic body radiation therapy for inoperable early stage lung cancer. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H. JAMA. 2010;303(11):1070-6.

25) Tomotherapy after Pleurectomy/Decortication or Biopsy for Malignant Pleural Mesothelioma Allows the Delivery of High Dose of Radiation in Patients with Intact Lung. Emilio Minatel, Marco Trovo, Jerry Polesel, Imad Abu Rumeileh, Tania Baresic, Alessandra Bearz, Alessandro Del Conte, Giovanni Franchin, Carlo Gobitti, Annalisa Drigo, Andrea Dassie, Vittore Pagan, Mauro G. Trovo. Journal of Thoracic Oncology. 2012; 7(12): 1862-1866.

26) Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and Etoposide. Andrew T. Turrisi, M.D., Kyungmann Kim, Ph.D., Ronald Blum, M.D., William T. Sause, M.D., Robert B. Livingston, M.D., Ritsuko Komaki, M.D., Henry Wagner, M.D., Seena Aisner, M.D., and David H. Johnson, M.D.
New England Journal of Medicine. 1999; 340:265-271.

27) The utility of non-axial treatment beam orientations for lower lobe lung cancers. Brian Quaranta, Shiva Das, Timothy D. Shafman, Kim Light, Lawrence Marks.  Journal of Applied Clinical Medical Physics. 2010; 11(1).

28) Variations in Target Volume Definition for Postoperative Radiotherapy in Stage III Non Small Cell Lung Cancer: Aanlysis of
An International Contouring Study.  Spoelstra, FB, Senan, S, Le Pe´Choux, C, Ishikura, S,  Casas, F,  Ball, D, Price, A, De Ruysscher, D, Van Sorensen Dekoste, R. International Journal of Radiation Oncology Biology Physics. 2010;76(4):1106–1113.